Skip to Content
Merck
CN

SML0293

Telbivudine

≥98% (HPLC)

Synonym(s):

β-L-Thymidine, 1-(2-Deoxy-β-L-erythro-pentofuranosyl)-5-methyl-2,4(1H,3H)-Pyrimidinedione, 2′-Deoxy-L-thymidine, Epavudine, L-Thymidine, NV 02B, Sebivo

Sign In to View Organizational & Contract Pricing

Select a Size

About This Item

Empirical Formula (Hill Notation):
C10H14N2O5
CAS Number:
3424-98-4
Molecular Weight:
242.23
MDL number:
MFCD02683612
UNSPSC Code:
12352200
PubChem Substance ID:
329825300
NACRES:
NA.77

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Quality Level

100

Assay

≥98% (HPLC)

form

powder

optical activity

[α]/D -15 to -22°, c = 1 in H2O

color

white to beige

solubility

H2O: 10 mg/mL (clear solution)

storage temp.

2-8°C

SMILES string

CC1=CN([C@@H]2C[C@@H](O)[C@H](CO)O2)C(=O)NC1=O

InChI

1S/C10H14N2O5/c1-5-3-12(10(16)11-9(5)15)8-2-6(14)7(4-13)17-8/h3,6-8,13-14H,2,4H2,1H3,(H,11,15,16)/t6-,7+,8+/m1/s1

InChI key

IQFYYKKMVGJFEH-CSMHCCOUSA-N

Application

Telbivudine has been used to explore the mechanisms of telbivudine (LdT) induced creatine kinase (CK) elevation.

Biochem/physiol Actions

Telbivudine is a nucleoside analog that is widely used to treat hepatitis B virus (HBV) infection.
Telbivudine is a synthetic molecule containing β-L-configuration. Telbivudine improves the estimated glomerular filtration rate (eGFR) in response to chronic hepatitis B (CHB). It prevents perinatal transmission and enhances the hepatitis B e antigen (HBeAg) seroconversion. It is also known to cause side effects such as creatine kinase (CK) elevation and fatal rhabdomyolysis.
Telbivudineis a Hepatitis B antiviral agent.

Pictograms

Exclamation mark
GHS07

Signal Word

Warning

Hazard Statements

H302

Precautionary Statements

P264 - P270 - P301 + P312 - P501

Hazard Classifications

Acute Tox. 4 Oral

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000509955
0000509953
0000509953
0000509955
0000493605

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Faezeh Koohestani et al.
PloS one, 8(9), e75844-e75844 (2013-09-17)
Uterine leiomyomas (ULs) are benign tumors occurring in the majority of reproductive aged women. Despite the high prevalence of these tumors, little is known about their etiology. A hallmark of ULs is the excessive deposition of extracellular matrix (ECM), primarily
Xiao-Jian Zhou et al.
Antimicrobial agents and chemotherapy, 50(7), 2309-2315 (2006-06-28)
Two phase I studies were conducted to assess the plasma pharmacokinetics of telbivudine and potential drug-drug interactions between telbivudine (200 or 600 mg/day) and lamivudine (100 mg/day) or adefovir dipivoxil (10 mg/day) in healthy subjects. Study drugs were administered orally.
Ailin Chen et al.
Cancer communications (London, England), 41(2), 121-139 (2021-01-21)
Overexpression of Aurora-A (AURKA) is a feature of breast cancer and associates with adverse prognosis. The selective Aurora-A inhibitor alisertib (MLN8237) has recently demonstrated promising antitumor responses as a single agent in various cancer types but its phase III clinical
Zhaoping Yan et al.
Medicine, 97(31), e11716-e11716 (2018-08-05)
The aim of this study was to evaluate clinical efficacy of telbivudine in treatment of hepatitis B virus-associated glomerulonephritis (HBV-GN).A total of 43 HBV-GN patients combined with chronic hepatitis B were treated with telbivudine for 104 weeks. Serum levels of
Gang Huang et al.
Annals of surgery, 268(6), 943-954 (2018-03-10)
Despite antiviral treatment has been shown to reduce hepatocellular carcinoma (HCC) recurrence after curative treatment for hepatitis B virus (HBV)-related HCC in patients with high preoperative HBV-DNA levels, it is still unclear whether antiviral therapy is useful in reducing recurrence
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service